CE InformationDownload MaterialsCourse Progress
  • Access Webinar
  • Evaluation
  • Certificate
Evaluation

Harnessing the Utility of Selective Sphingosine 1-Phosphate Receptor Modulators to Optimize Patient Care in IBD

Evaluation

HMP Education would appreciate your feedback on the quality and impact of this activity.

Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little).

To what extent are you able to better achieve each of the following learning objectives?

Describe the mechanisms of action of S1PR modulators and the implications for IBD management
Evaluate the most current clinical data associated with available and emerging S1PR modulators
Implement personalized treatment plans for patients with IBD by incorporating appropriate predictive biomarker analysis, improving patient communication, and addressing barriers to adherence

Please rate the faculty on the following:

Raymond K. Cross, Jr., MD, MS, AGAF, FACG : Knowledge, expertise, and teaching ability

Please rate the following components relating to this activity:

Content
Relevance to your practice 
Educational format 
Audience-participation portions (eg., Q&A, polling, pre/post-testing) 
Resources and/or other materials supporting the activity
Overall

Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices.

How many patients with IBD do you see during a typical week? 

Do you feel like there were any new data presented?

Did you learn anything new?

Did you gain confidence on the new information?

Did this program include opportunities to learn as a part of a healthcare team?
S1PR modulators indirectly antagonize the receptor’s function leading to which of the following?
In a recent open-label extension study, approximately half of the patients with moderate to severe UC who did not meet clinical response after 10 weeks of ozanimod therapy benefited from an additional ______ weeks of ozanimod therapy.

Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific.
How confident are you in your ability to incorporate emerging therapies into IBD management strategies to address suboptimal outcomes in appropriate patients?
What challenges or barriers outside of your control may prevent you from changing your practice?
255 characters max

The information presented in this activity did not serve to advance a proprietary interest of any commercial entity.
Based on my participation in this activity, I anticipate I will more often: (select all that apply)